<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842230</url>
  </required_header>
  <id_info>
    <org_study_id>142HPS13001</org_study_id>
    <nct_id>NCT01842230</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine</brief_title>
  <acronym>CKD-345 DDI</acronym>
  <official_title>A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine After Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic
      properties of Telmisartan/S-amlodipine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In the steady state Telmisartan 80mg and S-amlodipine 5mg AUClast</measure>
    <time_frame>Telmisartan: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, 48hr post-dose, S-amlodipine:Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168hr post-dose</time_frame>
    <description>AUClast = Area under the plasma concentration-time curve from zero time until the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the steady state Telmisartan 80mg and S-amlodipine 5mg Cmax</measure>
    <time_frame>Telmisartan: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, 48hr post-dose, S-amlodipine: Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168hr post-dose</time_frame>
    <description>Cmax=Maximum Plasma Drug Concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In the steady state Telmisartan 80mg &amp; S-amlodipine 5mg AUCinf</measure>
    <time_frame>Telmisartan: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, 48hr post-dose, S-amlodipine:Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168hr post-dose</time_frame>
    <description>AUCinf=Area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Telmisartan 80mg &amp; S-amlodipine 5mg Tmax</measure>
    <time_frame>Telmisartan: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, 48hr post-dose, S-amlodipine:Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168hr post-dose</time_frame>
    <description>Tmax=Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Telmisartan 80mg &amp; S-amlodipine 5mg T1/2</measure>
    <time_frame>Telmisartan: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 24, 36, 48hr post-dose, S-amlodipine:Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168hr post-dose</time_frame>
    <description>T1/2=Observed terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>From 1day to 22 days</time_frame>
    <description>Evaluated safety parameters included: Physical examination, vital sign, Laboratory test, ECG
Adverse event monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg and S-amlodipine 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</intervention_name>
    <description>Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
Atorvastatin 40mg: 1 tablet, oral, once daily, 2days
over the period I &amp; II(cross-over)</description>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg and S-amlodipine 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg and S-amlodipine 5mg</intervention_name>
    <description>Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
over the period I &amp; II(cross-over)</description>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg and S-amlodipine 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 20 aged and 45 aged in healthy male and female

          2. Body weight more than 55kg in male, 50kg in female

          3. Body Mass Index more than 18.5 and under 25 (Body Mass Index(kg/m2)= kg/(m)2) 4.If
             female, must include more than one among the items

               1. The menopause (there is no natural menses for at least 2 years)

               2. Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition)

               3. The male partner infertility before screening (Demonstrated azoospermia after
                  vasectomy)and if this man is the only partner of the female subject.

               4. you are using one of the following contraceptive measure for 3 months before
                  screening, and Necessarily you agree that used continuously contraceptive measure
                  during the clinical trial and for 1 month after the final dosing investigational
                  product.(But, should not use a device of contraception or oral contraceptive drug
                  that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium
                  drug interactions during the clinical trials)

                    -  Abstinence.

                    -  Physical interrupt method (such as a condom, contraceptive diaphoretic or
                       cervical cap)

               5. In case of women of childbearing age, the serum β-hCG pregnancy test is negative,
                  and urine β-hCG test is negative before taking the investigational product.

        5.If men has sexual life with women of childbearing age, Necessarily he agrees that use
        condoms during clinical trials and do not sperm donation during clinical trials and until
        one month after the final dosage of investigational products 6.Those who fully understand
        about this clinical trial after enough hearing, and then decided to join the clinical
        trials by themselves and to comply with the precautions written consent.

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system(severe hepatic
             impairment, etc), kidney(severe renal impairment, etc.), nervous system, immune
             system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular
             system (heart failure, etc.).or mental illness, or a history of mental disease.

          2. Have a gastrointestinal disease history that can affect drug absorption (Crohn's
             disease, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery)

          3. hypersensitivity reaction to drug or clinically significant hypersensitivity reaction
             in the history of Investigational drugs (telmisartan, s-amlodipine or atorvastatin
             calcium) or additives.

          4. An impossible one who participates in clinical trial including screening tests(medical
             history taking, BP, physical examination, 12-lead ECG, blood &amp; urine laboratory test
             result) before 28 days the taking Investigational Products.

          5. Defined by the following laboratory parameters:

               1. AST, ALT&gt; 1.25* upper limit of normal range

               2. Total bilirubin &gt; 1.5* upper limit of normal range

               3. CPK &gt; 1.5* upper limit of normal range

               4. eGFR(using by MDRD method) &lt; 60 mL/min/1.73m2

          6. Sitting SBP &gt; 150 mmHg or &lt; 90 mmHg, Sitting DBP&gt; 100 mmHg or &lt; 50 mmHg , after
             5minuts break.

          7. Drug abuse or have a history of drug abuse showed a positive for urine drug test.

          8. Pregnant or lactating women.

          9. A heavy caffeine consumer(caffeine&gt;5cups/day), alcohol consumer(alcohol&gt;210g/week), or
             smoker(cigarette&gt;10cigarettes/day)

         10. Subject takes ethical drug or herbal medicine within 14days, OTC within 7days before
             the beginning of study treatment but investigator determine that the taking drug
             affect this study or could affect the safety of the subjects.

         11. Subject who takes inhibitors and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30 days.

         12. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days
             before the beginning of study treatment)

         13. Subject who treated with any investigational drugs within 60days before the beginning
             of study treatment (However, biologicals applies for 90 days, but can be based on a
             more extended period of time by considering the half-life)

         14. Previously donate whole blood within 60 days or component blood within 30days.

         15. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

         16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telminuvo</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>S-amlodipine</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

